Principal Financial Group Inc Lineage Cell Therapeutics, Inc. Transaction History
Principal Financial Group Inc
- $167 Billion
- Q1 2025
A detailed history of Principal Financial Group Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Principal Financial Group Inc holds 12,740 shares of LCTX stock, worth $8,408. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,740
Previous 13,700
7.01%
Holding current value
$8,408
Previous $6,000
16.67%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding LCTX
# of Institutions
138Shares Held
108MCall Options Held
8KPut Options Held
3K-
Broadwood Capital Inc New York, NY49.6MShares$32.7 Million1.86% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$6.31 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.92MShares$5.89 Million0.0% of portfolio
-
Defender Capital, Llc.6.31MShares$4.17 Million1.19% of portfolio
-
Raffles Associates LP New York, NY5.64MShares$3.72 Million3.45% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $112M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...